Supplement industry news and updates – November 2023

12 standout ingredients from SupplySide West 2023—slideshow

From 1,447 exhibitors, Natural Product Insider editors chose a dozen favorite innovative solutions for new supplement launches. Click through for a peek at new ingredients that may heat up female libido while turning down hot flashes, boost gamers’ reaction times and one that may lull users to sleep with the world’s first whole food-derived melatonin. Read more here.

SupplySide education poll reveals findings on DSHEA, FDA warning letters and counterfeits –– article
A lively discussion with five industry attorneys and live audience polling revealed insights about industry challenges and preferred priorities. Read on and dig deeper to see whether you agree or find the information surprising. You can share your views with the editor. Read more here.

‘Risky times’ for homeopathic products — article

“There has never been a riskier time than now to sell homeopathic products, as FDA’s crackdown on companies selling them continues…including big names such as Boiron,” writes dietary supplement consultant Asa Waldstein in his quarterly FDA warning letter roundup. Read about what else FDA is cracking down on here.

Up to speed on the FDA Foreign Supplier Verification Program Rule? — article

Many are not. Failure to implement the program is one of the fastest-growing deficiencies for food and ingredient inspections. The Consumer Healthcare Products Association’s Larisa Pavlick breaks down what you and your suppliers need to know to be prepared and offers helpful tips in this deep dive. Read more here.

7 ingredient trends from SPINS — article

Immunity’s crashing and burning. Protein continues to explode (despite the New York Times). And a source of natural Viagra surges by 67%. Find out what SPINS sales data from the first half of 2023 reveals about ingredient and supplement sales and what it all means for the future. Read more here.

FDA warns about probiotics for preemies — article

FDA issued a formal warning about the use of the ingredient with preterm infants after a second warning letter was sent to a company marketing a probiotic product for that use. One of those letters followed the death of an infant. Get the background and the latest research on the strains involved here.